Seven Fleet Capital Management LP Purchases Shares of 200,141 Inventiva S.A. Sponsored ADR $IVA

Seven Fleet Capital Management LP purchased a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 1st quarter, HoldingsChannel reports. The fund purchased 200,141 shares of the company’s stock, valued at approximately $1,111,000.

A number of other hedge funds also recently made changes to their positions in the stock. Paradigm Biocapital Advisors LP acquired a new position in shares of Inventiva in the fourth quarter worth approximately $18,600,000. ADAR1 Capital Management LLC acquired a new stake in Inventiva during the 4th quarter valued at approximately $12,601,000. UBS Group AG raised its holdings in Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. SymBiosis Capital Partners LLC bought a new position in Inventiva during the 4th quarter worth approximately $12,090,000. Finally, Millennium Management LLC lifted its position in shares of Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock worth $12,334,000 after purchasing an additional 2,540,540 shares during the period. 19.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on IVA. Wall Street Zen lowered shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Finally, Cantor Fitzgerald initiated coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $16.56.

Inventiva Stock Down 3.0%

NASDAQ IVA opened at $4.48 on Friday. The business has a 50 day simple moving average of $4.20 and a 200 day simple moving average of $5.30. Inventiva S.A. Sponsored ADR has a one year low of $3.16 and a one year high of $7.98.

Inventiva Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.